Aomori Tohru, Sakurai Hiroomi, Nishihara Hiroshi
Division of Hospital Pharmacy Science, Keio University Faculty of Pharmacy.
Department of Pharmacy, Keio University Hospital.
Pharmacogenet Genomics. 2022 Aug 1;32(6):242-245. doi: 10.1097/FPC.0000000000000476. Epub 2022 Jun 9.
Cancer genomic medicine (CGM) is a medical service that provides optimized treatment for each patient based on genes, biomarkers, environment, and lifestyle. In Japan, the approval of designed core hospitals for CGM started in 2017. In June 2019, two types of cancer gene panel tests became available in the national health insurance system, and CGM was socially implemented. While CGM is still in its infancy and there are some issues that need to be resolved, there are cases where the treatment has shown dramatic results. The present review highlights the CGM system in Japan, the issues it faces, and the role of pharmacists in this system.
癌症基因组医学（CGM）是一种基于基因、生物标志物、环境和生活方式为每位患者提供优化治疗的医疗服务。在日本，2017年开始批准指定核心医院开展CGM。2019年6月，两种癌症基因检测面板在国民健康保险体系中可用，CGM得以在社会层面实施。虽然CGM仍处于起步阶段，存在一些需要解决的问题，但也有治疗取得显著成效的案例。本综述重点介绍了日本的CGM系统、其所面临的问题以及药剂师在该系统中的作用。
